Comparisons

Trulicity vs. Ozempic: Comparing Dulaglutide and Semaglutide for Diabetes and Weight Loss

GLP-1 Companion · 8 min read

Quick answer

Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly GLP-1 injections for type 2 diabetes, but they differ meaningfully in weight loss efficacy, cardiovascular outcomes, and HbA1c reduction. Here is the head-to-head evidence.

Trulicity (dulaglutide) and Ozempic (semaglutide) are two of the most widely prescribed once-weekly GLP-1 receptor agonists for type 2 diabetes. Both are injected once per week, work through similar mechanisms, and have demonstrated cardiovascular benefits. However, they differ substantially in their weight loss efficacy, glycemic potency, and the breadth of their cardiovascular evidence. This article compares the two using the best available clinical trial data.

Mechanism: The Same Class, Different Molecules

Both dulaglutide and semaglutide are GLP-1 receptor agonists — they bind to the GLP-1 receptor and activate it, producing insulin release, glucagon suppression, slower gastric emptying, and reduced appetite. Both are given by subcutaneous injection once weekly.

The key structural difference: semaglutide has been engineered for more potent and sustained GLP-1 receptor activation, which translates to meaningfully greater metabolic effects at the doses used in clinical practice. Dulaglutide uses a different albumin-binding strategy, resulting in a similar half-life but lower receptor-binding potency.

Dosing

Trulicity (dulaglutide): Starting dose 0.75 mg once weekly; can be increased to 1.5 mg, 3.0 mg, or 4.5 mg (higher doses added in 2020).
Ozempic (semaglutide): Starting dose 0.25 mg once weekly for 4 weeks, then 0.5 mg; can increase to 1.0 mg and 2.0 mg.
Both use auto-injector pens with a hidden needle — Trulicity's device is particularly user-friendly and is often cited as easier to use for injection-anxious patients.

Head-to-Head: AWARD-11 vs. SUSTAIN Trials

No single trial has directly compared Trulicity and Ozempic at their maximum doses side-by-side in a randomized controlled trial. However, data from their respective clinical programs allows meaningful comparison.

HbA1c Reduction

Trulicity 0.75 mg: ~−0.7–0.8% HbA1c reduction
Trulicity 1.5 mg: ~−1.0–1.1%
Trulicity 4.5 mg (highest dose): ~−1.6% (AWARD-11 trial)
Ozempic 0.5 mg: ~−1.4–1.5%
Ozempic 1.0 mg: ~−1.5–1.8%
Ozempic 2.0 mg: ~−1.8–2.0%

At equivalent dose levels, semaglutide generally produces larger HbA1c reductions. At maximum doses, Ozempic 2 mg has a slight edge over Trulicity 4.5 mg, though both are effective.

Weight Loss

Trulicity 1.5 mg: Approximately 2–3 kg (4–7 lbs) weight loss in most trials
Trulicity 3.0 mg: Approximately 4.2 kg (9.3 lbs) in AWARD-11
Trulicity 4.5 mg: Approximately 4.7 kg (10.4 lbs) in AWARD-11
Ozempic 1.0 mg: Approximately 4–6 kg (9–13 lbs) across SUSTAIN trials
Ozempic 2.0 mg: Approximately 6–7 kg (13–15 lbs)

Semaglutide (Ozempic) produces approximately 50–100% more weight loss than dulaglutide (Trulicity) at equivalent treatment durations and dose levels in clinical trials. For patients whose primary goal is significant weight loss, Ozempic is the stronger option.

Cardiovascular Outcomes

Both medications have demonstrated cardiovascular benefit in major outcome trials, a key requirement for first-line use in patients with established cardiovascular disease.

Trulicity — REWIND trial (2019): A 12% relative risk reduction in the composite of MACE (cardiovascular death, non-fatal MI, non-fatal stroke) vs. placebo in patients with type 2 diabetes. Notably, REWIND had a broader population than most outcomes trials — it included patients with only cardiovascular risk factors (not just established disease), suggesting dulaglutide may benefit lower-risk patients too.
Ozempic — SUSTAIN-6 trial (2016): A 26% relative risk reduction in MACE vs. placebo. As noted, this was a smaller trial designed for non-inferiority, so the magnitude should be interpreted carefully.
Semaglutide — SELECT trial (2023): A 20% MACE reduction in patients with obesity and established cardiovascular disease (no diabetes required). This broadens the cardiovascular indication significantly.

Side Effects Comparison

Both medications share the GI side-effect profile typical of GLP-1 receptor agonists: nausea, vomiting, diarrhea, constipation, and abdominal pain. Rates are broadly similar, with some nuances:

Nausea: Approximately 12–20% with both medications during dose escalation; typically resolves within weeks.
Injection site reactions: Trulicity's device design may result in slightly fewer injection-site bruises for some users.
Discontinuation due to side effects: 5–7% for both in clinical trials.
Both carry a boxed warning for thyroid C-cell tumor risk and should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.

Cost and Insurance

Trulicity list price: Approximately $900–$1,000/month
Ozempic list price: Approximately $935–$1,350/month
Both manufacturers offer copay savings programs for commercially insured patients (potential reduction to $25–$150/month)
Insurance formulary: Trulicity is preferred on some commercial formularies; Ozempic is preferred on others. Checking your specific plan is essential before prescribing.

Device Usability

Trulicity has a well-regarded auto-injector pen with a single-step activation mechanism and a hidden needle, which many injection-anxious patients find significantly easier to use. Ozempic also uses an easy-to-use pen, but with a visible needle that must be screwed on before each use. For patients with significant needle phobia, Trulicity's device may reduce the psychological barrier to adherence.

Which Is Right for You?

Choose Ozempic if: Maximizing weight loss and blood sugar reduction are priorities; you have obesity-related cardiovascular disease (SELECT trial benefit); or your insurance covers it at lower cost.
Choose Trulicity if: Your primary goal is glycemic control with modest weight loss; you are injection-anxious and prefer the single-step device; REWIND data for lower-risk CV patients is relevant to your profile; or your insurance strongly favors dulaglutide.
Discuss with your provider: Individual response to GLP-1 medications varies. Starting with one and switching if response is inadequate is a reasonable clinical approach.

The Bottom Line

Both Trulicity (dulaglutide) and Ozempic (semaglutide) are effective, once-weekly GLP-1 receptor agonists with proven cardiovascular benefits. Ozempic has an edge in weight loss efficacy, glycemic potency, and cardiovascular evidence breadth (especially with the SELECT trial). Trulicity's simpler device and slightly different cardiovascular trial population make it a viable alternative, particularly for patients where injectable ease and cardiovascular risk profile align. Talk to your doctor about which is the better fit for your individual needs.